NCT01274598已完成1 期
Open Label Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Occurrence of adverse events that are possibly or probably related to administration of LGG
研究概览
简要总结
This is a phase I, open label clinical trial to evaluate the safety of Lactobacillus rhamnosus GG (LGG) in elderly subjects. Lactobacilli are part of the normal flora of the intestine. LGG is one of several strains of Lactobacilli that is used as a probiotic or microorganism administered to confer "health benefits". Our research is focused on studying the possible therapeutic effects of LGG. The study hypotheses are:
- LGG administered twice daily will be safe and well tolerated in elderly subjects
- LGG will colonize the stool of elderly subjects and will modify the diversity and richness of the microbiota in their nasopharyngeal and stool specimens
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 80 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 65-80 years
- •Willing to complete the informed consent process
- •Able and willing to participate for the planned duration of the study, including availability for follow-up telephone contact
- •Willing to comply with protocol and report on compliance and side effects during the study period
- •Informed consent obtained and signed prior to screening
排除标准
- •Consumption of supplements or food products containing LGG or probiotics for 28 days prior to the start of the study or consumption of yogurt that has the "live and active cultures" seal.
- •Known or suspected allergies to probiotics, Lactobacillus, microcrystalline cellulose, gelatin, or antibiotics that may be used to treat LGG bacteremia or infection (i.e., subject able to tolerate at least 2 of the following regimens - Ampicillin or other beta lactam antibiotic, and Clindamycin, and Moxifloxacin).
- •Received oral or parenteral antibiotics within 4 weeks of enrollment or prescribed antibiotics on the day of enrollment
- •Drug or alcohol abuse within the previous 12 months
- •Hospitalization, major surgery or endoscopy within the last 3 months
- •Scheduled hospital admission within 3 months of enrollment
- •Resident of a nursing home or rehabilitation center
- •Presence of any of the following:
- •Grade 2 or higher abnormal vital signs or abnormalities on physical exam
- •Indwelling catheter or implanted hardware/prosthetic device or feeding tube
- •Active bowel leak, acute abdomen, colitis, or active GI disease or history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, history of gastrointestinal tract cancer or inflammatory bowel disease
- •History of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease
- •Underlying structural heart disease such as abnormal native heart valve or congenital abnormality, previous history of endocarditis or valve replacement, Stage IV congestive heart failure
- •History of peripheral vascular disease or stroke
- •Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy, neutrophil count <500/mm3, or an anticipated drop in the neutrophil count to <500/mm3 or active or planned chemotherapy or radiotherapy
- •History of collagen vascular or autoimmune disease
- •End stage renal disease
- •History of chronic obstructive pulmonary disease or asthma
- •Diabetes or thyroid disease
- •Active TB
- •Positive drug or alcohol testing at screening or positive breathalyzer at baseline or an unwillingness to undergo drug and alcohol testing
- •Abnormal laboratory tests defined as any of the following:
- •White blood cell (WBC) < 3.3 or > 12.0 K/µL
- •Platelets < 125 K/µL
- •Hemoglobin Males: < 12.0 g/dL; Females: < 11.0 g/dL
- •Creatinine > 1.8 mg/dL
- •Blood urea nitrogen (BUN) >27 mg/dL
- •Aspartate aminotransferase (AST) > 1.25 ULN
- •Alanine aminotransferase (ALT) > 1.25 ULN
- •Alkaline phosphatase > 2.0 ULN
- •Bilirubin (total) > 1.5 ULN
- •Glucose (non-fasting ) >126 mg/dL
- •Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody
- •Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study or would make it unlikely the subject could complete the study
结局指标
主要结局
Occurrence of adverse events that are possibly or probably related to administration of LGG
时间窗: through day 56
Adverse events will be detected during study visits with standardized questionnaires, medical history, vital signs, physical examinations, laboratory tests and review of subject diaries as well as between study visits on telephone calls based on responses to adverse event questionnaires.
次要结局
- Changes in the richness and bacterial diversity of the nasopharyngeal and gut microbiota and presence of LGG in stool specimens by routine culture(through day 56)
研究者
Patricia L. Hibberd
Chief, Division of Global Health; Department of Pediatrics
Massachusetts General Hospital
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic PatientsPeanut AllergyNCT02960074Rima Rachid15
招募中
1 期
A Study of GLB-001 in Patients With Myeloid MalignanciesPolycythemia VeraEssential ThrombocythemiaMyelodysplastic SyndromesMyeloid MalignancyMyelofibrosisAcute Myeloid LeukemiaNCT06378437Hangzhou GluBio Pharmaceutical Co., Ltd.108
已完成
1 期
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral DrugsHIV-1-infectionHepatic ImpairmentNCT03706898Viriom36
已完成
1 期
MEDI5752 in Japanese Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT05685472AstraZeneca6
进行中（未招募）
1 期
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Neurofibromatosis 1Neurofibroma PlexiformNCT04590235AstraZeneca32